Han Kun advises on Abbisko's listing in Hong Kong
October, 2021 - Beijing, Mainland China
Han Kun Law Offices advised and acted as PRC counsel to the company in connection with the global offering and listing of Abbisko Cayman Limited ("Abbisko", Stock Code: 2256) on the Main Board of The Stock Exchange of Hong Kong Limited. This is yet another landmark project Han Kun has recently advised on in the biotechnology industry in relation to listing under Chapter 18A of the Hong Kong Listing Rules.
Abbisko is a pioneer in the field of small molecule oncology therapies and has been dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies in China and globally. Abbisko has assembled an R&D team with ample experience in characterizing various types of cancers and identifying key genetic drivers of these diseases. Based on these findings, Abbisko is driven to discover and develop next-generation innovative small molecule therapies to treat patients and improve the quality of their lives.
We wish Abbisko continued success in the years to come!
